Medigen Biotechnology Capital Reinvestment Ratio
Medigen Biotechnology capital reinvestment ratio. Medigen Biotechnology (3176) has a Capital Reinvestment Ratio of 0.06x as of December 2024, meaning it reinvests 0% of its operating cash flow (NT$156.75 Million) in capital expenditures (NT$9.09 Million). Check cash flow reinvestment rate of Medigen Biotechnology to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Medigen Biotechnology (2003–2024)
Capital reinvestment ratio of Medigen Biotechnology from 2003 to 2024. This chart tracks Medigen Biotechnology's Capital Reinvestment Ratio across 5 annual periods. Also explore 3176 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Medigen Biotechnology Capital Reinvestment Ratio by Year (2003–2024)
Medigen Biotechnology capital reinvestment ratio by year from 2003 to 2024. For the full cash flow conversion analysis, see Medigen Biotechnology operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.55x | NT$37.92 Million | NT$58.68 Million | ▲ +453.9% |
| 2021 | 0.28x | NT$517.45 Million | NT$144.55 Million | ▼ -84.1% |
| 2015 | 1.75x | NT$294.18 Million | NT$515.25 Million | ▲ +4303.1% |
| 2005 | 0.04x | NT$80.72 Million | NT$3.21 Million | ▲ +347.7% |
| 2003 | 0.01x | NT$445.46 Million | NT$3.96 Million | — |